Dynavax Technologies Corporation
Index- P/E7.64 EPS (ttm)1.34 Insider Own0.20% Shs Outstand126.35M Perf Week-10.02%
Market Cap1.30B Forward P/E- EPS next Y-0.07 Insider Trans-92.39% Shs Float126.11M Perf Month-11.80%
Income228.40M PEG- EPS next Q0.33 Inst Own95.20% Short Float12.44% Perf Quarter-16.95%
Sales673.80M P/S1.92 EPS this Y172.60% Inst Trans16.80% Short Ratio7.64 Perf Half Y-10.18%
Book/sh3.35 P/B3.06 EPS next Y-104.00% ROA22.90% Target Price25.50 Perf Year-47.76%
Cash/sh4.10 P/C2.50 EPS next 5Y- ROE91.30% 52W Range7.26 - 21.39 Perf YTD-27.22%
Dividend- P/FCF9.12 EPS past 5Y16.90% ROI29.00% 52W High-53.02% Beta1.36
Dividend %- Quick Ratio2.60 Sales past 5Y108.90% Gross Margin61.80% 52W Low38.43% ATR0.56
Employees311 Current Ratio2.80 Sales Q/Q385.80% Oper. Margin38.00% RSI (14)31.87 Volatility5.41% 4.70%
OptionableYes Debt/Eq0.52 EPS Q/Q2778.50% Profit Margin33.90% Rel Volume0.32 Prev Close10.24
ShortableYes LT Debt/Eq0.52 EarningsAug 04 AMC Payout0.00% Avg Volume2.05M Price10.05
Recom1.80 SMA20-9.37% SMA50-23.23% SMA200-17.41% Volume593,095 Change-1.86%
Jan-06-22Resumed Goldman Buy $38
Aug-06-21Initiated Goldman Buy $19
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Sep-22-22 06:15PM
Sep-20-22 07:29AM
Sep-19-22 07:43PM
Sep-15-22 11:54AM
Sep-12-22 06:15PM
Sep-10-22 10:53AM
Sep-08-22 04:05PM
Sep-05-22 07:17PM
Aug-30-22 09:35AM
Aug-29-22 07:42PM
Aug-25-22 10:31AM
Aug-12-22 03:45PM
Aug-08-22 09:55AM
Aug-06-22 05:00AM
Aug-05-22 03:43PM
Aug-04-22 06:35PM
Jul-21-22 05:09PM
Jun-30-22 10:50AM
Jun-28-22 07:51AM
Jun-27-22 09:13AM
Jun-23-22 05:04PM
Jun-20-22 07:36AM
Jun-13-22 08:12PM
Jun-05-22 07:13AM
May-25-22 04:05PM
May-21-22 08:49AM
May-20-22 12:53PM
May-19-22 06:01PM
May-16-22 06:46PM
May-13-22 04:17PM
May-12-22 06:16PM
May-08-22 07:31AM
May-06-22 09:01AM
May-05-22 06:05PM
May-04-22 02:25PM
May-03-22 07:20AM
Apr-21-22 04:05PM
Apr-05-22 04:02PM
Apr-03-22 02:55PM
Mar-18-22 09:20AM
Mar-17-22 10:51AM
Mar-08-22 04:05PM
Mar-03-22 04:05PM
Mar-01-22 07:08PM
Feb-28-22 08:30PM
Feb-26-22 06:45AM
Feb-25-22 11:15AM
Feb-24-22 09:05AM
Feb-23-22 04:05PM
Feb-20-22 02:27AM
Feb-17-22 03:02PM
Feb-16-22 04:05PM
Feb-15-22 12:40PM
Feb-03-22 12:06PM
Feb-02-22 04:05PM
Feb-01-22 08:44AM
Jan-27-22 12:16PM
Jan-21-22 05:28AM
Jan-19-22 12:53PM
Jan-10-22 08:00AM
Jan-07-22 04:05PM
Jan-05-22 04:05PM
Dec-31-21 06:15PM
Dec-29-21 05:55PM
Dec-28-21 01:54PM
Dec-23-21 08:09AM
Dec-14-21 08:10AM
Dec-05-21 08:39AM
Dec-03-21 04:15PM
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hack Andrew A. F.DirectorAug 15Sale14.683,000,00044,040,0005,415,000Aug 17 05:17 PM
Janssen RobertSenior Vice PresidentAug 09Sale16.927,938134,27735,519Aug 10 08:59 PM
Novack David FPresident & COOAug 09Sale16.9226,250444,03753,213Aug 10 08:55 PM
Spencer RyanCEO and DirectorAug 09Sale16.9214,921252,399144,513Aug 10 08:43 PM
CANO FRANCISDirectorAug 08Option Exercise4.9715,00074,55035,834Aug 10 08:21 PM
CANO FRANCISDirectorAug 08Sale17.1715,000257,55020,834Aug 10 08:21 PM
Burgess JustinPrincipal Accounting OfficerMay 17Sale10.006,00060,0003,854May 18 06:16 PM
Novack David FPresident & COOMar 03Sale10.5741,862442,48173,213Mar 04 09:18 PM
Spencer RyanCEO and DirectorMar 03Sale10.5683,108877,923129,771Mar 04 08:16 PM
Burgess JustinPrincipal Accounting OfficerMar 03Sale10.5821,490227,3643,854Mar 04 08:03 PM
Janssen RobertSenior Vice PresidentMar 03Sale10.5724,036253,99824,707Mar 04 08:04 PM
Spencer RyanCEO and DirectorFeb 10Option Exercise0.0089,2500160,839Feb 14 09:09 PM
Janssen RobertSenior Vice PresidentNov 17Option Exercise10.4753,431559,42361,707Nov 18 05:06 PM
Janssen RobertSenior Vice PresidentNov 17Sale17.0753,431912,2928,276Nov 18 05:06 PM
Janssen RobertSenior Vice PresidentNov 16Option Exercise10.4735,974376,64844,250Nov 18 05:06 PM
Janssen RobertSenior Vice PresidentNov 16Sale17.1635,974617,4798,276Nov 18 05:06 PM
Novack David FPresident & COONov 01Sale20.1220,000402,40044,066Nov 02 05:30 PM
Novack David FPresident & COOOct 07Sale18.003,00054,00064,066Oct 08 05:59 PM
Novack David FPresident & COOOct 01Sale18.2317,000309,84467,066Oct 05 07:04 PM